Skip to main navigation

Community
Science
Careers
- Life at Rhythm
- Working at Rhythm
About
- Senior Management
- Board of Directors
Investor Relations
Contact Us

INVESTOR RELATIONS

Overview
Events & Presentations
Stock Information
SEC Filings
Corporate Governance
News
Contact IR

News

Year

December 1, 2022

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference

November 21, 2022

Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

November 8, 2022

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

November 8, 2022

Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update

November 7, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

November 3, 2022

Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®

November 2, 2022

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023

November 1, 2022

Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

October 25, 2022

Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022

October 12, 2022

Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022

October 6, 2022

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

October 6, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

September 23, 2022

Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

September 19, 2022

Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering

September 19, 2022

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

September 14, 2022

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

September 14, 2022

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

September 7, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

September 6, 2022

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

September 1, 2022

Rhythm Pharmaceuticals to Present at Investor Conferences in September

August 8, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

August 3, 2022

Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference

August 2, 2022

Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update

July 28, 2022

Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022

July 22, 2022

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

July 20, 2022

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

July 18, 2022

NICE Recommends Rhythm’s ▼IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

July 12, 2022

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

July 8, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

June 22, 2022

Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency

June 22, 2022

Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment

June 16, 2022

Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

June 16, 2022

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome

June 13, 2022

Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022

June 13, 2022

Rhythm Pharmaceuticals Presents Initial Data from Long-term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

June 2, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 5, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 4, 2022

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference

May 3, 2022

Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update

May 2, 2022

Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting

April 26, 2022

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

April 8, 2022

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

April 6, 2022

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

March 1, 2022

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

March 1, 2022

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

February 23, 2022

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

February 22, 2022

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

February 16, 2022

Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

February 8, 2022

Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

January 13, 2022

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

RHYTHM

Contact Us

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

COMMUNITY

SCIENCE

MC4R Pathway
Our Research
Our Pipeline
Our Focus
Clinical Studies
Expanded Access
Publications and Presentations
GOLD Academy
Glossary

CAREERS

Life at Rhythm
Working at Rhythm

ABOUT

Senior Management
Board of Directors

INVESTORS & MEDIA

Overview
Events and Presentations
Stock Information
SEC Filings
Corporate Governance
News
Contact IR

© 2022 Rhythm Pharmaceuticals, Inc. All Rights Reserved.
Rhythm, GOLD Academy, LEAD for Rare Obesity, Uncommon Obesity, Uncovering Rare Obesity, and their corresponding logos are trademarks of Rhythm Pharmaceuticals, Inc.

Terms of Use Privacy Policy